3dGRO^® Endometrial Organoids (291T)

Endometrial organoids are advanced three-dimensional cell culture systems derived from endometrial tissue, effectively mimicking the architecture and functionality of the uterus. These organoids serve as critical models for studying endometrial cancer, which includes various histological types with distinct biological behaviors and clinical outcomes.The predominant subtype, Endometrioid Adenocarcinoma, constitutes approximately 75-80% of endometrial cancer cases and is classified as Type I, often linked to estrogen exposure and diagnosed at earlier stages. In contrast, aggressive variants such as Serous Papillary Carcinoma (10-15%) and Clear Cell Carcinoma (5-10%) are classified as Type II endometrial cancers, frequently diagnosed at advanced stages and associated with poorer outcomes. Serous Papillary Carcinoma is particularly aggressive, characterized by high-grade features and mutations in the p53 gene, contributing to its malignancy and poor prognosis.The complexity of endometrial cancer is further illustrated by Mixed Endometrial Carcinoma, which contains multiple cancerous cell types, and Uterine Carcinosarcoma, which combines carcinoma and sarcoma components. Additionally, Undifferentiated Carcinoma, another Type II variant, presents unique challenges due to its aggressive nature. Rare variants, such as neuroendocrine tumors and lymphoepithelial-like carcinoma, further contribute to the diversity of endometrial cancers, emphasizing the need for accurate diagnosis and staging.We offer two lines of endometrial organoids, 274T and 291T, both derived from the serous type of endometrial cancer. The 274T organoid line is positive for PTEN, p53, MUC1, and Pan CD44 expression, while the 291T organoid line is positive for PTEN, MUC16 (CA-125), and MUC1. Both lines are negative for Estrogen Receptor (ER) and Progesterone Receptor (PR). These organoids enable researchers to investigate the unique properties of these aggressive cancer types, facilitating the exploration of personalized treatment options and enhancing our understanding and management of endometrial diseases.3dGRO^® organoids were derived utilizing HUB Organoid Technology. The purchaser of this product shall agree to HUB’s terms of use (listed below), which shall be separately acknowledged and accepted by such purchaser, prior to transfer of this product to purchaser. Cell Line Characteristics:

• Sex: Female
• Age: 68 Years
• Organ: Endometrium (Primary Tumor)
• Disease: Serous Papillary Carcinoma

Cryopreserved patient derived endometrial cancer organoids (PDOs).

Store in liquid nitrogen. The organoids can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

3dGRO^® is a trademark of Merck KGaA, Darmstadt, Germany. 3dGRO^® organoids were derived utilizing HUB Organoid Technology.The purchaser of this product shall agree to HUB’s terms of use, which shall be separately acknowledged and accepted by such purchaser, prior to transfer of this product to purchaser.

3dGRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.